The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
VA Office of Research and Development
Tizona Therapeutics, Inc
Essen Biotech
IDEAYA Biosciences
Weill Medical College of Cornell University
University of Kentucky
University of California, San Francisco
University of California, San Francisco
University of Wisconsin, Madison
OHSU Knight Cancer Institute
Twinpig Biolab, Inc.
Jonsson Comprehensive Cancer Center
BioXcel Therapeutics Inc
Amgen
Maastricht University Medical Center
OHSU Knight Cancer Institute
Lava Therapeutics
Peter MacCallum Cancer Centre, Australia
University of California, San Francisco
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Duke University
Icahn School of Medicine at Mount Sinai
University of Southern California
Merck Sharp & Dohme LLC